Systemic therapy for advanced hepatocellular carcinoma has expanded at an
unprecedented pace over the past 5 years. After tyrosine kinase inhibitors dominated the …

Simple Summary Neutrophil-to-lymphocyte ratio (NLR) as a prognostic indicator of patients
treated with immunotherapy has been fully reported. However, the dynamics of NLR after …

Objective We conducted the first meta-analysis to identify the predictive significance of
baseline blood biomarkers (such as neutrophil to lymphocyte ratio (NLR), early alpha …

Abstract Background & Aims Atezolizumab plus bevacizumab (Ate/Bev) has demonstrated
efficacy and safety in patients with advanced hepatocellular carcinoma (HCC) in the phase …

Background Atezolizumab plus bevacizumab was approved for hepatocellular carcinoma
(HCC) patients in 2020, but treatment outcomes of atezolizumab plus bevacizumab in real …

Hepatocellular carcinoma (HCC) is the most common primary liver cancer worldwide. The
onset of the disease is occult and develops rapidly. As a result, the disease is often detected …

Purpose: Inter-tumoral heterogeneity at the differential lesion level raises the possibility of
distinct organ-specific responses to immune checkpoint inhibitors (ICIs). We aimed to …

Hepatocellular carcinoma (HCC) is a common and deadly cancer worldwide. Many factors
contribute to mortality and place an individual at high risk of developing HCC, including viral …

Background and aims The impacts of macrovascular invasion (MVI) or extrahepatic spread
(EHS) on the efficacy and safety of immune checkpoint inhibitors (ICIs) among …

Background The definition of hyperprogressive disease (HPD) is controversial in the
literature and has not been widely described in melanoma. The aim of this study was to …